Gastric cancer†: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Radiotherapy and Oncology

Volumn 110, Issue 1, 2014, Pages 189-194

  Waddell, Tom ^a   Verheij, Marcel ^b   Allum, William ^c   Cunningham, David ^a   Cervantes, Andrés ^d   Arnold, Dirk ^e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; CANCER INCIDENCE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; LAPAROSCOPY; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH CANCER; TREATMENT PLANNING; CANCER STAGING; STOMACH NEOPLASMS;

FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 84896089384     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.09.015     Document Type: Review

References (48)

1. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
2. D. Forman, and V.J. Burley Gastric cancer: global pattern of the disease and an overview of environmental risk factors Best Pract Res Clin Gastroenterol 20 2006 633 649 (Pubitemid 44391336)
3. R.C. Fitzgerald, R. Hardwick, and D. Huntsman et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research J Med Genet 47 2010 436 444
4. J. Nath, K. Moorthy, and P. Taniere et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma Br J Surg 95 2008 721 726
5. G.W. de Graaf, A.A. Ayantunde, and S.L. Parsons et al the role of staging laparoscopy in oesophagogastric cancers Eur J Surg Oncol 33 2007 988 992 (Pubitemid 47408736)
6. L. Sobin, M. Gospodarowicz, and C. Wittekind TNM classification of malignant tumours 7th ed. 2009 Wiley-Blackwell Oxford
7. S. Edge, D. Byrd, and C. Compton et al. AJCC cancer staging manual 7th ed. 2010 Springer New York (NY)
8. M. Tada, Y. Tanaka, and N. Matsuo et al. Mucosectomy for gastric cancer: current status in Japan J Gastroenterol Hepatol 15 2000 D98 D102
9. T. Gotoda, M. Iwasaki, and C. Kusano et al. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria Br J Surg 97 2010 868 871
10. J.J. Bonenkamp, J. Hermans, and M. Sasako et al. Extended lymph-node dissection for gastric cancer N Engl J Med 340 1999 908 914 (Pubitemid 29141051)
11. A. Cuschieri, P. Fayers, and J. Fielding et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial the Surgical Cooperative Group Lancet 347 1996 995 999 (Pubitemid 26112171)
12. I. Songun, H. Putter, and E.M. Kranenbarg et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial Lancet Oncol 11 2010 439 449
13. L. Jiang, K.H. Yang, and Q.L. Guan et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis J Surg Oncol 107 2013 807 814
14. J.L. Dikken, J.W. van Sandick, and W.H. Allum et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe Br J Surg 100 2013 83 94
15. M.A. Memon, S. Khan, and R.M. Yunus et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma Surg Endosc 22 2008 1781 1789
16. L. Haverkamp, T.J. Weijs, and P.C. van der Sluis et al. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis Surg Endosc 27 2013 1509 1520
17. D. Cunningham, W.H. Allum, and S.P. Stenning et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
18. M. Ychou, V. Boige, and J.P. Pignon et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial J Clin Oncol 29 2011 1715 1721
19. D. Cunningham, N. Starling, and S. Rao et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
20. S.R. Smalley, J.K. Benedetti, and D.G. Haller et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection J Clin Oncol 30 2012 2327 2333
21. J.L. Dikken, E.P. Jansen, and A. Cats et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer J Clin Oncol 28 2010 2430 2436
22. S. Kim, D.H. Lim, and J. Lee et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach Int J Radiat Oncol Biol Phys 63 2005 1279 1285 (Pubitemid 41628018)
23. J. Lee, H. Lim do, and S. Kim et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial J Clin Oncol 30 2012 268 273
24. W.G. Zhu, D.F. Xua, and J. Pu et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection Radiother Oncol 104 2012 361 366
25. X. Paoletti, K. Oba, and T. Burzykowski et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 303 2010 1729 1737
26. M. Sasako, S. Sakuramoto, and H. Katai et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer J Clin Oncol 29 2011 4387 4393
27. S.H. Noh, S.R. Park, and H.K. Yang et al. Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial Ann Oncol 24 2013 iv14
28. A.D. Wagner, W. Grothe, and J. Haerting et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2006 2903 2909 (Pubitemid 46630593)
29. N. Starling, S. Rao, and D. Cunningham et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J Clin Oncol 27 2009 3786 3793
30. A.F. Okines, A.R. Norman, and P. McCloud et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer Ann Oncol 20 2009 1529 1534
31. M. Dank, J. Zaluski, and C. Barone et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 2008 1450 1457
32. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 2006 4991 4997 (Pubitemid 46631401)
33. P.C. Thuss-Patience, A. Kretzschmar, and D. Bichev et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2011 2306 2314
34. J.H. Kang, S.I. Lee, and H. Lim do et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 2012 1513 1518
35. H. Ford, A. Marshall, and J. Wadsley et al. COUGAR-02: a randomised phase III study of docetaxel versus active symptom control in advanced oesophagogastric adenocarcinoma J Clin Oncol 31 2013 (Meeting Abstracts)
36. A.C. Roy, S.R. Park, and D. Cunningham et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma Ann Oncol 24 2013 1567 1573
37. S. Ueda, S. Hironaka, and H. Yasui et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial J Clin Oncol 30 2012 (Meeting Abstracts)
38. J. Tey, M.F. Back, and T.P. Shakespeare et al the role of palliative radiation therapy in symptomatic locally advanced gastric cancer Int J Radiat Oncol Biol Phys 67 2007 385 388 (Pubitemid 46108314)
39. N. Deng, L.K. Goh, and H. Wang et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets Gut 61 2012 673 684
40. Y.J. Bang, E. Van Cutsem, and A. Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial Lancet 376 2010 687 697
41. A. Ohtsu, M.A. Shah, and E. Van Cutsem et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study J Clin Oncol 29 2011 3968 3976
42. C.S. Fuchs, J. Tomasek, and J.Y. Cho et al. REGARD: a phase III, randomized, doubleblinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy J Clin Oncol 31 2013 (Meeting Abstracts)
43. F. Lordick, Y.K. Kang, and H.C. Chung et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Lancet Oncol 14 2013 490 499
44. T. Waddell, I. Chau, and D. Cunningham et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Lancet Oncol 14 2013 481 489
45. D.R. Ferry, S.J. Dutton, and W. Mansoor et al. Phase III multi-centre, randomised, doubleblind, placebo-controlled trials of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (cancer oesophagus gefitinib) Ann Oncol 23 2012 ixe12 (LBA20-PR)
46. W.H. Allum, J.M. Blazeby, and S.M. Griffin et al. Guidelines for the management of oesophageal and gastric cancer Gut 60 2011 1449 1472
47. IGCC Working Group the charter scaligero on gastric cancer: follow-up after gastrectomy for cancer. In: 10th International Gastric Cancer Congress (IGCC); 2013.
48. D. D'Ugo, A. Biondi, A. Tufo, and R. Persiani Follow-up: the evidence Dig Surg 30 2013 159 168